LYRA - חוב כולל להון Lyra Therapeutics Inc
Lyra Therapeutics, Inc. (LYRA) brings together top-tier drug delivery specialists attracted by competitive compensation and the opportunity to achieve a breakthrough in otolaryngology. The business relies on the stable US legal environment, where ethical standards minimize political risks. The development of ENT products is based on the outsourcing of trials and manufacturing. This price chart reflects a total debt-to-equity ratio of 0.00.
%20-%20%D7%99%D7%97%D7%A1%20%D7%9B%D7%9C%D7%9C%20%D7%94%D7%97%D7%95%D7%91%D7%95%D7%AA%20%D7%9C%D7%9E%D7%A7%D7%95%D7%A8%D7%95%D7%AA%20%D7%A2%D7%A6%D7%9E%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_LYRA_-_Lyra-Therapeutics-Inc._-_All-Debt-to-Shareholders-Equity-Ratio "LYRA (Lyra Therapeutics, Inc.) היסטוריית חוב כולל להון מ-04.07.2022 עד 28.03.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Lyra Therapeutics, Inc.
To build a resilient portfolio, I assess business dependence on creditors via the total liabilities-to-equity ratio, which determines the issuer's financial autonomy. In the case of Lyra Therapeutics, Inc. (LYRA), low leverage combined with the high pricing power of the unique XTreo matrix minimizes debt service risks, as evidenced by the stable ratio of debt to equity.